{"organizations": [], "uuid": "b9b8979cfcf295cc6c082df9f3597946050266b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-tetraphase-posts-top-line-results/brief-tetraphase-posts-top-line-results-from-ignite3-phase-3-clinical-trial-of-eravacycline-in-cuti-idUSASB0C5HK", "country": "US", "domain_rank": 408, "title": "BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-13T23:12:00.000+02:00", "replies_count": 0, "uuid": "b9b8979cfcf295cc6c082df9f3597946050266b3"}, "author": "", "url": "https://www.reuters.com/article/brief-tetraphase-posts-top-line-results/brief-tetraphase-posts-top-line-results-from-ignite3-phase-3-clinical-trial-of-eravacycline-in-cuti-idUSASB0C5HK", "ord_in_thread": 0, "title": "BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI", "locations": [], "entities": {"persons": [{"name": "eravacycline", "sentiment": "none"}], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "ciai", "sentiment": "none"}, {"name": "clinical trial of eravacycline in cuti reuters", "sentiment": "none"}, {"name": "reuters) - tetraphase pharmaceuticals inc", "sentiment": "none"}, {"name": "cuti", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 13, 2018 / 9:13 PM / Updated 9 minutes ago BRIEF-Tetraphase Posts Top-Line Results From IGNITE3 Phase 3 Clinical Trial Of Eravacycline In CUTI Reuters Staff 1 Min Read Feb 13 (Reuters) - Tetraphase Pharmaceuticals Inc: * TETRAPHASE ANNOUNCES TOP-LINE RESULTS FROM IGNITE3 PHASE 3 CLINICAL TRIAL OF ERAVACYCLINE IN COMPLICATED URINARY TRACT INFECTIONS (CUTI) * TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE DID NOT ACHIEVE CO-PRIMARY ENDPOINTS IN CUTI TRIAL​ * TETRAPHASE PHARMACEUTICALS INC - ‍ERAVACYCLINE WAS WELL TOLERATED IN IGNITE3​ * TETRAPHASE - ‍CONTINUES TO PREPARE FOR COMMERCIALIZATION OF ERAVACYCLINE AS A TREATMENT FOR CIAI IN U.S. AND EUROPE, ASSUMING REGULATORY APPROVAL​ * TETRAPHASE PHARMACEUTICALS INC - ‍CONTINUE TO MOVE FORWARD WITH OUR REGISTRATION STRATEGY FOR ERAVACYCLINE IN COMPLICATED INTRA-ABDOMINAL INFECTIONS​ * TETRAPHASE PHARMACEUTICALS- STUDY FAILED TO MEET CO-PRIMARY EFFICACY ENDPOINTS OF RESPONDER RATE IN MICRO-ITT POPULATION AT EOI TREATMENT VISIT, TOC VISIT Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-13T23:12:00.000+02:00", "crawled": "2018-02-13T23:29:30.010+02:00", "highlightTitle": ""}